{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:46:04Z","timestamp":1794653164972,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11523-025-01130-y","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:53:07Z","timestamp":1743274387000},"page":"519-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["A Phase 1b\/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors"],"prefix":"10.1007","volume":"20","author":[{"given":"Cathy","family":"Eng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal J.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Kardosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Shihadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Howland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Randolph","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"1130_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomatarum I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1130_CR2","unstructured":"National Cancer Institute. SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Published 2023. Accessed November, 30, 2023."},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clcc.2015.05.006","volume":"14","author":"MS Lee","year":"2015","unstructured":"Lee MS, Kopetz S. Current and future approaches to target the epidermal growth factor receptor and its downstream signaling in metastatic colorectal cancer. Clin Colorectal Cancer. 2015;14:203\u201318.","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"1130_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2217\/bmm-2016-0358","volume":"11","author":"G Kafatos","year":"2017","unstructured":"Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, et al. RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. Biomark Med. 2017;11(9):751\u201360.","journal-title":"Biomark Med"},{"issue":"12","key":"1130_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","volume":"27","author":"CJ Allegra","year":"2009","unstructured":"Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti\u2013epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091\u20136.","journal-title":"J Clin Oncol"},{"key":"1130_CR6","unstructured":"Erbitux (cetuximab). Prescribing information. Eli Lilly and Company. 2019."},{"issue":"20","key":"1130_CR7","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040\u20138.","journal-title":"N Engl J Med"},{"issue":"8","key":"1130_CR8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.bjc.6603685","volume":"96","author":"F Di Fiore","year":"2007","unstructured":"Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007;96(8):1166\u20139.","journal-title":"Br J Cancer"},{"issue":"17","key":"1130_CR9","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, O\u2019Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"1130_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271\u201385.","journal-title":"Cell"},{"issue":"2","key":"1130_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"issue":"3","key":"1130_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41375-019-0622-6","volume":"34","author":"H Kamijo","year":"2020","unstructured":"Kamijo H, Miyagaki T, Takahashi-Shishido N, Nakajima R, Oka T, Suga H, et al. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia. 2020;34(3):845\u201356.","journal-title":"Leukemia"},{"issue":"7","key":"1130_CR13","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126(7):2610\u201320.","journal-title":"J Clin Invest"},{"issue":"2","key":"1130_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/jclinpath-2020-206611","volume":"74","author":"H Kim","year":"2021","unstructured":"Kim H, Bang S, Jee S, Paik SS, Jang K. Clinicopathological significance of CD47 expression in hepatocellular carcinoma. J Clin Pathol. 2021;74(2):111\u20135.","journal-title":"J Clin Pathol"},{"issue":"4","key":"1130_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/diagnostics11040668","volume":"11","author":"H Kim","year":"2021","unstructured":"Kim H, Jee S, Kim Y, Sim J, Bang S, Son HK, et al. Correlation of CD47 expression with adverse clinicopathologic features and an unfavorable prognosis in colorectal adenocarcinoma. Diagnost (Basel). 2021;11(4):668.","journal-title":"Diagnost (Basel)."},{"issue":"17","key":"1130_CR16","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mittra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109(17):6662\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1130_CR17","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/cam4.1894","volume":"8","author":"JH Wang","year":"2019","unstructured":"Wang JH, Huang ST, Zhang L, Liu ZG, Liang RX, Jiang SW, et al. Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma. Cancer Med. 2019;8(3):1315\u201325.","journal-title":"Cancer Med"},{"key":"1130_CR18","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.2147\/OTT.S245023","volume":"13","author":"Z-H Wang","year":"2020","unstructured":"Wang Z-H, Pei X-F, Zhu Z-Q, Lin Z, Mao YY, Xu XL, et al. CD47 overexpression is associated with Epstein\u2013Barr virus infection and poor prognosis in patients with nasopharyngeal carcinoma. Onco Targets Ther. 2020;13:3325\u201334.","journal-title":"Onco Targets Ther"},{"key":"1130_CR19","doi-asserted-by":"publisher","unstructured":"Zhao H-J, Pan F, Shi Y-C, Luo X, Ren R-R, Peng L-H, et al. Prognostic significance of CD47 in human malignancies: a systematic review and meta-analysis. Transl Cancer Res. 2018;7(3). https:\/\/doi.org\/10.21037\/tcr.2018.05.31.","DOI":"10.21037\/tcr.2018.05.31"},{"issue":"2","key":"1130_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R. The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225\u201332.","journal-title":"Curr Opin Immunol"},{"issue":"5473","key":"1130_CR21","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"P-A Oldenborg","year":"2000","unstructured":"Oldenborg P-A, Zheleznyak A, Fang Y-F, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051\u20134.","journal-title":"Science"},{"issue":"27","key":"1130_CR22","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng D, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA. 2013;110(27):11103\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1130_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10(9): e0137345.","journal-title":"PLoS One"},{"issue":"12","key":"1130_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37(12):946\u201353.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1130_CR25","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;41(15):2815\u201326.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1130_CR26","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018;379(18):1711\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"1130_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699\u2013713.","journal-title":"Cell"},{"issue":"2","key":"1130_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/19420862.2017.1409319","volume":"10","author":"B Liu","year":"2018","unstructured":"Liu B, Guo H, Xu J, Qin T, Guo Q, Gu N, et al. Elimination of tumor by CD47\/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. MAbs. 2018;10(2):315\u201324.","journal-title":"MAbs"},{"issue":"2","key":"1130_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","volume":"28","author":"J Theruvath","year":"2022","unstructured":"Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022;28(2):333\u201344.","journal-title":"Nat Med"},{"key":"1130_CR30","doi-asserted-by":"crossref","unstructured":"Chao MP, McKenna KM, Cha A, Feng D, Liu J, Sikic BI, et al. Abstract PR13: the anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies. Cancer Immunol Res. 2016; 4(11_Suppl):PR13.","DOI":"10.1158\/2326-6066.IMM2016-PR13"},{"key":"1130_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.946850","volume":"12","author":"C Cremolini","year":"2023","unstructured":"Cremolini C, Montagut C, Ronga P, Venturini F, Yamaguchi K, Stintzing S, et al. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol. 2023;12: 946850.","journal-title":"Front Oncol"},{"key":"1130_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","volume":"18","author":"B Gorovits","year":"2016","unstructured":"Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, et al. Pre-existing antibody: biotherapeutic modality-based review. AAPS J. 2016;18:311\u201320.","journal-title":"AAPS J"},{"key":"1130_CR33","doi-asserted-by":"crossref","unstructured":"Johnson L, Zhang Y, Su-Feher L, Lee Y, Sallman DA, Asch AS, et al. Abstract P699: Magrolimab alters the tumor microenvironment to improve bone marrow functions in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). Hemasphere. 2023; 7(S3):e45153c5.","DOI":"10.1097\/01.HS9.0000969700.45153.c5"},{"issue":"3","key":"1130_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cas.13162","volume":"108","author":"Y Inoue","year":"2017","unstructured":"Inoue Y, Hazama S, Suzuki N, Tokumitsu Y, Kanekiyo S, Tomochika S, et al. Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Sci. 2017;108(3):455\u201360.","journal-title":"Cancer Sci"},{"issue":"1","key":"1130_CR35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41392-021-00534-2","volume":"6","author":"H Liu","year":"2021","unstructured":"Liu H, Liang Z, Zhou C, Zeng Z, Wang F, Hu T, et al. Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):144.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01130-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01130-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01130-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T07:47:21Z","timestamp":1748245641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01130-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01130-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"F.S., Y.L., K.S., D.J., Y.H., and M.H. are employees of Gilead Sciences, Inc. KS holds stock or stock options for Gilead Sciences, Inc. B.J. received research funding from Bristol Myers Squibb and Syntrix, grants from Gateway for Cancer Research outside the submitted work, and performed consulting services and served on speakers bureau for Taiho Oncology, Insmed Oncology, Gritstone Bio, and Incyte. N.J.L. received institutional research funding from ALX Therapeutics, Ascentage, Asana, Beigene, Constellation Pharma\/MorphoSys, Alexion, Cerulean, Forty Seven, Alpine, Merck, Pfizer, InhibRx, Regeneron, Apexian, Formation Biologics (Forbius), Symphogen, CytomX, Sapience Therapeutics, Incyte, Jounce, Livzon, Northern Biologics, Innovent Biologics, Ikena, Odonate, Loxo, Alpine Biosciences, Mersana, Macrogenics, Helsinn, Seagen, Shattuck Labs, Samumed, Astellas, Alkermes, SK Life Sciences, KSQ Therapeutics, Tizona, Servier, Sapience, Repare Therapeutics, Gilead Sciences, Inc, Bristol Myers\/Celgene, GSK, Janssen, Artios, Arcus Bio, and Volastra; and served on speakers bureaus for Innovent Biologics and Ikena. C.E. received institutional research funding from Jannsen, Pfizer, Sumitomo, and Merck; served on a speakers bureau for Mirati; and performed consulting for AbbVie, Amgen, Hoopika, IGMs, Merck, and Taiho. A.K. has nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This trial was conducted in accordance with the US Food and Drug Administration and International Council for Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP), the Declaration of Helsinki, and local authority requirements. Institutional review boards or independent ethics committees approved the study conduct at each study site. All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers on the basis of submitted curriculum vitae and reflecting nonconflict of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Science\u2019s discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"G.A.F., M.P.C., F.S., Y.H., M.H., and C.E. carried out study conception and design; G.A.F., N.J.L., J.R.H., P.A.P., C.S., B.J., A.K., A.P., and C.E. carried out provision of study materials or patients; M.P.C., Y.L., K.S., D.J., and Y.H. carried out collection and assembly of data. All authors carried out data analysis and interpretation, manuscript writing, final approval of the manuscript, and are accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}